HOXC10 and lung carcinoma: To further explore the clinical benefit of HOXC10 inhibition in patients, we constructed a mini patient-derived xenograft (mini-PDX) model25,26 with KRASG12C mutant lung cancer bone metastasis (Fig. 3j).